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Abstract
Background: DNA methylation, which is most frequently the transference of a methyl group to the 5-carbon
position of the cytosine in a CpG dinucleotide, plays an important role in both normal development and diseases.
To date, several genome-wide methylome studies have revealed sex-biased DNA methylation, yet no studies have
investigated sex differences in DNA methylation by taking into account cellular heterogeneity. The aim of the
present study was to investigate sex-biased DNA methylation on the autosomes in human blood by adjusting for
estimated cellular proportions because cell-type proportions may vary by sex.
Methods: We performed a genome-wide DNA methylation profiling of the peripheral leukocytes in two sets of
samples, a discovery set (49 males and 44 females) and a replication set (14 males and 10 females) using Infinium
HumanMethylation450 BeadChips for 485,764 CpG dinucleotides and then examined the effect of sex on DNA
methylation with a multiple linear regression analysis after adjusting for age, the estimated 6 cell-type proportions,
and the covariates identified in a surrogate variable analysis.
Results: We identified differential DNA methylation between males and females at 292 autosomal CpG site loci
in the discovery set (Bonferroni-adjusted p < 0.05). Of these 292 CpG sites, significant sex differences were also
observed at 98 sites in the replication set (p < 0.05).
Conclusions: These findings provided further evidence that DNA methylation may play a role in the differentiation
or maintenance of sexual dimorphisms. Our methylome mapping of the effects of sex may be useful to understanding
the molecular mechanism involved in both normal development and diseases.
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Background
Sex differences have been widely observed not only in
genetics and hormones but also in expression of genes
and microRNA [1–4]. DNA methylation, which is most
frequently the transference of a methyl group to the
5-carbon position of the cytosine in a CpG dinucleotide,
is one of the major mechanisms of epigenetic modifica-
tions. This modification plays an important role in gene
expression, chromosomal stability, genomic imprinting,
X-chromosome inactivation, and mammalian develop-
ment [5, 6]. Recent genome-wide methylome studies
have revealed sex-biased DNA methylation in specific
genes on the autosomes of several tissues, such as the
blood, brain, and saliva [7–9, 4]. However, researchers
have not yet investigated the sex differences in DNA
methylation by taking into account cellular hetero-
geneity, although several studies have demonstrated
the effects of cellular heterogeneity on DNA methyla-
tion status [10–16], and cell-type proportions may
vary by sex.
To reveal sex differences in DNA methylation in
human blood, we conducted a genome-wide profiling
of DNA methylation by using peripheral leukocytes
and then examined sex-biased DNA methylation after
correcting the estimated cell-type proportions of each
sample.
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Ninety-three healthy subjects (49 males and 44 females;
mean age: 43.6 ± 12.3 years) for our discovery set and 24
healthy subjects (14 males and 10 females, mean age:
35.3 ± 11.9 years) for our replication set were recruited
from volunteers who comprised hospital staff, university
students, and company employees. There was no signifi-
cant age difference between male and female groups in
both sample sets (p > 0.05). All subjects who joined this
study were of unrelated Japanese origin and signed
written informed consent forms that were approved by
the institutional ethics committees of Tokushima Univer-
sity Graduate School and the Osaka University Graduate
School of Medicine.
DNA methylation methods
Genomic DNA was prepared from peripheral blood
samples. A bisulfite conversion of 500 ng of genomic
DNA was performed with the EZ DNA methylation kit
(Zymo Research). DNA methylation levels were assessed
with Infinium HumanMethylation450 BeadChips (Illumina
Inc.) according to the manufacturer’s instructions. This ar-
ray’s technical schemes, accuracy, and high reproducibility
have been described in previous papers [17–19]. Quantita-
tive measurements of DNA methylation were determined
for 485,764 CpG dinucleotides that covered 99 % of the
RefSeq genes and were distributed across whole gene re-
gions, including promoters, gene bodies, and 3′-untrans-
lated regions (UTRs). The arrays also covered 96 % of the
CpG islands (CGIs) from the UCSC database with addi-
tional coverage in CGI shores (0–2 kb from CGI) and
CGI shelves (2–4 kb from CGI). DNA methylation data
were analyzed using the methylation analysis module
within the BeadStudio software (Illumina Inc.). The DNA
methylation status of the CpG sites was calculated as the
ratio of the signal from a methylated probe relative to the
sum of both the methylated and unmethylated probes.
This value, known as β, ranges from 0 (completely
unmethylated) to 1 (fully methylated). For intra-chip nor-
malization of the probe intensities, we performed color
balance and background corrections on every set of 12
samples from the same chip by using internal control
probes. For quality control, β values with detection
p values ≥0.05 were treated as missing values. Qualified
CpG sites used in statistical analyses were defined as
follows: 1) autosomal CpGs with no missing values in all
subjects; 2) CpGs with no probe single nucleotide poly-
morphism (SNPs) at minor allele frequencies ≥5 % in the
HapMap-JPT population; 3) CpGs with no probe cross-
reactivity, and no SNPs at CpG sites and single-base
extension sites in a previous paper [20]. The final data set
included 345,235 CpG sites (promoter: 152,298; gene
body: 104,707; 3′-UTR: 10,306; intergenic region: 77,924;
CpG island: 117,528; CpG island shore; 84,341; CpG island
shelf: 30,207; others: 113,159). We deposited genome-wide
DNA methylation data to the Gene Expression Omnibus
(GEO) of the National Center for Biotechnology Informa-
tion under the accession number GSE67393.
Statistical analysis
The cell-type proportions (CD4 + T cell, CD8 + T cell,
CD56 + NK cell, CD19 + B cell, CD14 +monocyte, and
granulocyte) for each of the samples were estimated
using a published algorithm [21, 22] implemented in an
R-package “Minfi,” as we had done in our previous study
[15]. Surrogate variable analysis (SVA), which is a me-
thod for modeling the potential confounding factors that
may or may not be known, including technical factors
such as batch effects, can increase the biological accur-
acy and reproducibility of analyses in microarray studies
[23, 24]. We used SVA to identify the potential con-
founding factors in our microarray data as surrogate var-
iables (SVs). Then, we examined the influences of sex on
DNA methylation with a multiple linear regression ana-
lysis after adjusting for age, significant SVs (8 SVs in the
first set and 6 SVs in the replication set), and the esti-
mated 6 cell-type proportions, as in a previous study [8].
Bonferroni correction was applied at the 0.05 level for
multiple testing (nominal p value of 1.44 × 10−7). The
gene-ontology analysis was performed with the Database
for Annotation, Visualization and Integrated Discovery
(DAVID) [25].
Results
Estimated cell-type proportions between males and
females
We estimated 6 cell-type proportions using “Minfi”, a
flexible and comprehensive bioconductor package for
the analysis of Infinium DNA methylation microarrays
developed by Aryee et al. [21]. The average estimated
cellular proportions of the male and female groups are
shown in Fig. 1. Of the 6 cell types, 2 (CD8 + T cell and
CD56 + NK cell) showed small but significant differ-
ences between the two groups (Welch’s t test p < 0.05),
which could be confounding factors in determining
sex-differential DNA methylation sites.
Sex differences in DNA methylation in the blood
The DNA methylation levels of 93 subjects were
evaluated using Infinium HumanMethylation450 Bead-
Chips, and then the sex differences of these levels
between 49 males and 44 females were assessed using
a multiple linear regression analysis after adjusting for
age, the estimated cell-type proportions, and the SVs
identified in our SVA. Of the 345,235 CpG sites,
significant sex differences in DNA methylation were
observed at 292 CpG sites (nominal p < 1.44 × 10−7,
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Additional file 1). When we analyzed array data
without adjusting for the estimated cell-type pro-
portions, significant sex differences were observed at
417 CpG sites (Additional file 2), and 270 sites were
common between the results from the adjusted and
un-adjusted analyses. The reduction in differentially
methylated sites after cell proportion adjustment
suggests that the present statistical analysis has
the ability to lower false-positive detections of sex-
differential DNA methylation sites. Figure 2 shows
volcano plots of differentially methylated CpG sites
between males and females. Figure 3 shows a
quantile-quantile (Q-Q) plot of −log10P values, which
deviates from their expected values under the null
hypothesis. Of the 292 CpG sites, 237 sites (81.2 %)
showed higher methylation in females than in males.
Table 1 lists the top 20 CpG sites that showed signifi-
cant sex differences. When these 292 CpG sites were
classified into 4 different categories according to their
locations in the genes (promoter, gene body, 3′-UTR,
and intergenic region), 139 sites (47.6 %) were located
in the promoter regions, 59 sites (20.2 %) in gene
bodies, and 2 sites (0.7 %) in 3′-UTRs. When these
292 CpG sites were classified into 4 categories ac-
cording to the CpG content in the genes (CGI, CGI
shore, CGI shelf, and others), 139 sites (47.6 %) were
located in the CGIs, 10 sites (3.4 %) in CGI shores,
and 76 sites (26 %) in CGI shelves.
Fig. 1 Average estimated cellular proportions of male and female groups. The y axis is each of average estimated cellular proportions of CD8 + T cell,
CD4 + T cell, CD56 + NK cell, CD19 + B cell, CD14 +monocyte, and granulocyte. Significant differences between the two groups were observed in 2
cell types (CD8 + T cell and CD56 + NK cell) (Welch’s t test p < 0.05)
Fig. 2 Volcano plots of differentially methylated CpG sites between
males and females. This volcano plot shows the result of genome-wide
DNA methylation differences between 49 males and 44 females after
adjusting for the estimated cell mixture proportions. Average beta
difference (males-females) is shown on the x axis. Log10-converted
p value is shown on the y-axis. CpG loci that showed a p value of less
than 5 % after Bonferroni correction are colored red. Significant sex
differences in DNA methylation were observed at 292 CpG
sites (p < 1.44 × 10−7)
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Gene-ontology analysis
We used DAVID to perform a gene-ontology analysis of
the genes, which showed significant sex differences in
DNA methylation, and revealed enrichment of genes re-
lated to secretion and secretion by cell. Table 2 lists the
significant gene-ontology categories.
Validation of sex differences in an independent set of
samples
DNA methylation levels were measured in an inde-
pendent cohort of 14 males and 10 females using the
same Illumina DNA methylation arrays. Of the top 20
differentially methylated CpG sites between males and
females in the first set, the same directions (male >
female or male < female) were observed at all CpG sites,
and significant sex differences were also observed at 16
sites in the replication set (p < 0.05) (Table 1). Of the 292
differentially methylated CpG sites in the first set, signifi-
cant sex differences were also observed at 98 sites in the
replication set (p < 0.05).
Discussion
In this study, we conducted a genome-wide DNA
methylation profiling of the peripheral leukocytes
from non-psychiatric subjects using Infinium Human-
Methylation450 BeadChips and identified sex-biased
genes on autosomes by adjusting for the estimated
cell-type proportions. This blood study is the first to
reveal sex differences in DNA methylation by taking
into account cellular heterogeneity of blood in the
analysis.
We revealed that most of significant loci (81.2 %)
showed higher DNA methylation in females than in
males. This finding is consistent with the results of pre-
vious studies [4, 7–9]. However, the explanation for this
phenomenon is unclear. Gene-ontology analysis of bio-
logical process revealed that genes with sex differences
in DNA methylation on autosomes were related to
secretion and secretion by cell. Of these 8 secretion-
related genes, 5 genes (FKBP1B, SCIN, SMPD3, STEAP2,
and TRIM36) has been associated with prostate cancer
and hyperplasia [26–30]. These results may suggest some
hormone-related genes are sex-differentially regulated,
perhaps via methylation.
To date, two genome-wide methylome studies have
examined sex-biased DNA methylation using Illumina
Infinium HumanMethylation450 BeadChips [4, 9].
When we compared with the 614 sex-biased differen-
tial CpG sites on autosomes identified in a previous
study using the human prefrontal cortex tissues [4],
these CpG sites identified by Xu et al. were sig-
nificantly enriched for those sites identified in the present
study (common CpG site: 93 vs. 293, un-common CpG
site: 521 vs. 344,942, odds ratio (OR) = 210; 95 %
confidence intervals (CIs), 163–269; Fisher exact test
p < 0.05). When we compared with the top 20 sex-
biased differential CpG sites on autosomes in the
study of Xu et al. [4], we observed common sex-
biased DNA methylation at 17 CpG sites which cov-
ered 14 distinctive genes (ARID1B, C6orf108, GLUD1,
H3F3A, KRT77, SCIN, TFDP1, WBP11P1, YARS2, and
ZNF69) in our blood study. These results suggest that
sex-biased DNA methylation on autosomes in the
brain is also observed in peripheral blood in specific
genes, although tissue-specific differences in DNA
methylation have been reported [31, 32]. ARID1B,
which is a member of the SWI/SNF-A chromatin re-
modeling complex, has been implicated in intellectual
disability and autism spectrum disorders [33, 34]. GLUD1,
which plays a role at glutamatergic synapses [35], has been
implicated in schizophrenia [36]. H3F3A, which encodes
the replication-independent histone 3 variant H3.3, has
been implicated in glioblastoma [37, 38].
When we compared with the 564 sex-biased dif-
ferential genes on autosomes identified in a previous
study using the human blood mononuclear cells from
a high-aged cohort (over 95 years old) [9], we observed
common sex-biased DNA methylation in only 15 genes
(AGAP11, ANKRD11, C15orf29, HOXC4, HOXC5, HOXC6,
MACROD1, NOTCH4, NSD1, OSTalpha, PEX10, PTPRN2,
Fig. 3 Quantile-quantile (Q-Q) plot of DNA methylation between
males and females. The x axis is the expected −log10P value, and the
y axis is the observed −log10P value. This Q-Q plot shows a deviation
of the observed from the expected, providing evidence of DNA
methylation differences between males and females at numerous
CpG sites
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Table 1 Top 20 autosomal CpG sites with significant sex differences





























cg12691488 1 2.4E+08 CGI Intergenic 0.352 0.171 0.180 2.26E-38 0.263 0.111 0.152 2.11E-03
cg03618918 1 1.6E+08 Others Intergenic 0.790 0.691 0.099 6.38E-37 0.825 0.745 0.079 3.04E-03
cg17238319 RFTN1 3 1.6E+07 Others Gene body 0.660 0.788 −0.128 6.88E-34 0.703 0.816 −0.113 5.19E-02
cg25304146 WBP11P1 18 3E+07 Others Gene body 0.630 0.550 0.081 1.31E-32 0.704 0.604 0.100 5.78E-02
cg03691818 KRT77 12 5.3E+07 Others Gene body 0.043 0.178 −0.134 3.25E-32 0.052 0.254 −0.202 7.13E-04
cg17232883 11 5.9E+07 Others Intergenic 0.076 0.157 −0.081 4.72E-31 0.056 0.123 −0.067 1.42E-04
cg25568337 ARID1B 6 1.6E+08 Others Promoter 0.164 0.258 −0.093 1.07E-29 0.152 0.297 −0.145 1.15E-04
cg04946709 LOC644649 16 6E+07 CGI Gene body 0.805 0.631 0.175 1.37E-29 0.823 0.499 0.324 8.79E-05
cg22266749 COL25A1 4 1.1E+08 CGI Promoter 0.192 0.093 0.099 2.77E-27 0.229 0.107 0.122 1.52E-02
cg12177922 HAX1 1 1.5E+08 CGI Promoter 0.207 0.297 −0.090 4.68E-27 0.161 0.236 −0.074 3.68E-02
cg23719534 15 1E+08 CGI Intergenic 0.859 0.952 −0.093 6.67E-27 0.858 0.949 −0.091 3.87E-03
cg20299935 17 2.2E+07 Others Intergenic 0.708 0.811 −0.103 1.84E-26 0.740 0.813 −0.073 8.56E-01
cg12052203 B3GNT1 11 6.6E+07 CGI Promoter 0.172 0.035 0.136 6.19E-26 0.210 0.050 0.160 1.23E-03
cg06710937 13 2.3E+07 CGI Intergenic 0.062 0.191 −0.129 1.39E-25 0.036 0.173 −0.137 5.72E-04
cg23814743 NICN1 3 4.9E+07 CGI Promoter 0.239 0.277 −0.038 2.25E-25 0.121 0.158 −0.038 1.81E-03
cg15817705 1 2.1E+08 CGI shore Intergenic 0.750 0.662 0.088 2.73E-25 0.759 0.683 0.076 3.01E-02
cg03218192 AP2B1 17 3.4E+07 Others Promoter 0.276 0.365 −0.089 1.30E-24 0.228 0.344 −0.116 2.43E-03
cg07852945 TLE1 9 8.4E+07 CGI Promoter 0.103 0.177 −0.074 2.58E-24 0.047 0.137 −0.090 1.83E-04
cg23256579 PRR4 12 1.1E+07 Others Promoter 0.422 0.631 −0.209 2.97E-24 0.363 0.573 −0.210 4.33E-03
cg25294185 RNASEH2C 11 6.5E+07 CGI Gene body 0.171 0.064 0.107 1.88E-23 0.162 0.086 0.076 6.48E-01













SHANK3, TFDP1, and UNC84A) in our study. This
difference between studies might be due to the large
difference in subjects’ mean age and the fact that
Sun et al. did not correct for sex-differential cell-type
proportions. Both age and cell-type proportion are
well known to be major confounding factors in DNA
methylation [12, 16]. However, sex-biased genes iden-
tified by Sun et al. were significantly enriched for
those genes identified in the present study (common
gene: 15 vs. 193, un-common gene: 549 vs. 19,533,
OR = 2.8; 95 % CI, 1.5–4.7; Fisher exact test p < 0.05).
Mai and colleagues (2010) has demonstrated HoxC4-
mediated regulation of activation-induced cytosine
deaminase expression, as enhanced by estrogen, and
has suggested a possible role of this homeodomain
transcription factor in mediating immunopotentiation
in gestation and neonatal and adult life [39].
There are several limitations to the present study.
First, our sample size was not large. Replication stud-
ies with larger samples will be needed. Second, the
cellular proportions were created by a bioinformatics
tool, so these were not based on direct observation of
the relative numbers of cells in the sample. Fur-
thermore, experimental noises may be increased due
to the circular use of DNA methylation data, as these
data are used first to define cell-type proportions,
which are then used as covariates in the differential
methylation analysis. Cell-type-specific studies will be
needed. Third, we did not take other confounding
factors, such as smoking or body mass index, into
consideration in our analysis, which may affect DNA
methylation status [40, 41], because these information
were not collected in the present study.
Conclusions
In summary, we identified sex-biased DNA methyla-
tion at numerous CpG sites on autosomes by con-
ducting a comprehensive DNA methylation profiling
of blood and by adjusting for estimated cellular
proportions. These findings provided further evidence
that DNA methylation may play a role in the
differentiation or maintenance of sexual dimorphisms,
and our methylome mapping of the effects of sex
may be useful to understanding the molecular mech-
anism involved in normal development and diseases.
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Additional file 1: 292 CpG sites which showed significant gender
differences in DNA methylation at 5 % Bonferroni correction.
Additional file 2: 417 CpG sites which showed significant gender
differences in DNA methylation at 5 % Bonferroni correction.
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Table 2 Gene-ontology analysis of the genes which showed significant sex differences in DNA methylation in this study (p < 0.01)
Category Term Gene count (%) p value Fold enrichment
GOTERM_CC_FAT GO:0031965~ nuclear membrane 5 (3.36) 2.49.E-03 8.70
GOTERM_CC_FAT GO:0031301~ integral to organelle membrane 6 (4.03) 2.74.E-03 6.17
GOTERM_CC_FAT GO:0012505~ endomembrane system 15 (10.07) 2.84E-03 2.43
GOTERM_CC_FAT GO:0005635~ nuclear envelope 7 (4.70) 5.42.E-03 4.31
GOTERM_BP_FAT GO:0032940~ secretion by cell 7 (4.70) 5.85.E-03 4.25
GOTERM_CC_FAT GO:0031300~ intrinsic to organelle membrane 6 (4.03) 5.96.E-03 5.14
GOTERM_BP_FAT GO:0046903~ secretion 8 (5.37) 9.30.E-03 3.36
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